CHA₂DS₂-VASc Score Calculator for Atrial Fibrillation Stroke Risk

The CHA₂DS₂-VASc Score Calculator is a clinical tool used to estimate the risk of stroke and systemic thromboembolism in people with atrial fibrillation (AF).

Atrial fibrillation is an irregular heart rhythm that can increase the risk of blood clot formation inside the heart. These clots may travel to the brain and cause an ischaemic stroke.

The CHA₂DS₂-VASc scoring system evaluates important risk factors including congestive heart failure, hypertension, age, diabetes, previous stroke or transient ischaemic attack (TIA), vascular disease, and sex category.

Use this calculator to estimate your CHA₂DS₂-VASc score and understand your estimated stroke risk category.





Interpretation of CHA₂DS₂-VASc Score
Score 0 (Male) or 1 (Female)
Low estimated stroke risk.
Patients may have a low annual risk of thromboembolism. Clinical assessment should consider individual factors before deciding on anticoagulation.
Score 1 (Male)
Low to intermediate stroke risk.
The benefits and risks of oral anticoagulation should be considered based on individual patient factors and clinical guidelines.
Score ≥2
Higher stroke risk.
Patients with a higher CHA₂DS₂-VASc score may benefit from stroke prevention strategies, including consideration of oral anticoagulant therapy.
What Does CHA₂DS₂-VASc Stand For?
CHA₂DS₂-VASc is an abbreviation representing the clinical risk factors used in the scoring system:
  • C – Congestive heart failure / left ventricular dysfunction
  • H – Hypertension
  • A₂ – Age ≥75 years (2 points)
  • D – Diabetes mellitus
  • S₂ – Previous stroke, TIA or systemic embolism (2 points)
  • V – Vascular disease
  • A – Age 65–74 years
  • Sc – Sex category (female)
Why Is CHA₂DS₂-VASc Score Used?
The CHA₂DS₂-VASc score helps healthcare professionals estimate stroke risk in patients with non-valvular atrial fibrillation.
Atrial fibrillation increases the risk of blood clots due to abnormal blood flow within the atria. Identifying patients at increased risk helps guide decisions regarding stroke prevention treatment.
CHA₂DS₂-VASc Score and Anticoagulation
A higher CHA₂DS₂-VASc score may indicate an increased need to consider anticoagulation therapy.
Common anticoagulant medicines used for stroke prevention in atrial fibrillation include:
  • Direct oral anticoagulants (DOACs)
    • Apixaban
    • Rivaroxaban
    • Dabigatran
    • Edoxaban
  • Vitamin K antagonists
    • Warfarin
The decision to start anticoagulation should always be made with a healthcare professional after considering bleeding risk, patient preference, and clinical circumstances.
Limitations of CHA₂DS₂-VASc Calculator
The CHA₂DS₂-VASc score estimates stroke risk but does not provide a diagnosis or replace medical assessment.
The score should be interpreted alongside other clinical factors, including:
When Should You Seek Medical Advice?
Speak with a healthcare professional if you:
  • Have been diagnosed with atrial fibrillation
  • Experience palpitations, dizziness or chest discomfort
  • Have questions about stroke prevention medicines
  • Are considering starting or stopping anticoagulant treatment
Frequently Asked Questions (FAQ)
What is a CHA₂DS₂-VASc score?
The CHA₂DS₂-VASc score is a clinical risk assessment tool used to estimate stroke risk in patients with atrial fibrillation.
What is a normal CHA₂DS₂-VASc score?
A lower score indicates a lower estimated stroke risk. The interpretation depends on sex, age and individual clinical factors.
What CHA₂DS₂-VASc score requires anticoagulation?
A higher score generally indicates greater stroke risk and may support consideration of oral anticoagulant therapy.
Can CHA₂DS₂-VASc be used for all types of atrial fibrillation?
The score is mainly validated for patients with non-valvular atrial fibrillation.
Does a CHA₂DS₂-VASc score predict bleeding risk?
No. It estimates stroke risk only. Separate tools such as HAS-BLED may be used to assess bleeding risk.
Medical Disclaimer
This CHA₂DS₂-VASc calculator is provided for educational purposes only and should not replace professional medical advice, diagnosis, or treatment decisions.